Patents by Inventor Eun Sook Chung

Eun Sook Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arylamine-fluorene alternating copolymer, electroluminescence device material, and electroluminescence device using the polymer
    Patent number: 11917899
    Abstract: An arylamine-fluorene alternating copolymer having a structural unit (A) is represented by Chemical Formula (1): wherein Chemical Formula (1) is the same as described in the detailed description.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: February 27, 2024
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Masashi Tsuji, Takahiro Fujiyama, Yusaku Konishi, Dae Young Chung, Fumiaki Kato, Jaejun Chang, Keigo Furuta, Takao Motoyama, Eun Joo Jang, Hyo Sook Jang, Tae Ho Kim, Tomoyuki Kikuchi, Yuho Won
  • Pharmaceutical composition comprising bee venom-phospholipase A2 (BV-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity
    Patent number: 9956270
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 1, 2018
    Assignee: INIST ST CO., LTD.
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi
  • Pharmaceutical composition comprising bee venom-phospholipase A2 (bv-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity
    Patent number: 9919035
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 20, 2018
    Assignee: INIST ST CO., LTD.
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi
  • PHARMACEUTICAL COMPOSITION COMPRISING BEE VENOM-PHOSPHOLIPASE A2 (BV-PLA2) FOR TREATING OR PREVENTING DISEASES RELATED TO DEGRADATION OF ABNORMAL REGULATORY T CELL ACTIVITY
    Publication number: 20170173120
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 22, 2017
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi
  • PHARMACEUTICAL COMPOSITION COMPRISING BEE VENOM-PHOSPHOLIPASE A2 (BV-PLA2) FOR TREATING OR PREVENTING DISEASES RELATED TO DEGRADATION OF ABNORMAL REGULATORY T CELL ACTIVITY
    Publication number: 20170165328
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 15, 2017
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi
  • Pharmaceutical composition comprising bee venom-phospholipase A2 (BV-PLA2) for treating or preventing diseases related to degradation of abnormal regulatory T cell activity
    Patent number: 9526767
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: December 27, 2016
    Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi
  • PHARMACEUTICAL COMPOSITION COMPRISING BEE VENOM-PHOSPHOLIPASE A2 (BV-PLA2) FOR TREATING OR PREVENTING DISEASES RELATED TO DEGRADATION OF ABNORMAL REGULATORY T CELL ACTIVITY
    Publication number: 20150150951
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: June 4, 2015
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi